Paliperidone for irritability in adolescents and young adults with autistic disorder (Q47291177)

13 January 2018

title

Paliperidone for irritability in adolescents and young adults with autistic disorder (English)

1 reference

13 January 2018

0 references

1 reference

Christopher J McDougle

5

object named as

Christopher J McDougle

1 reference

13 January 2018

Kimberly A Stigler

1

1 reference

13 January 2018

Jennifer E Mullett

2

1 reference

13 January 2018

Craig A Erickson

3

1 reference

13 January 2018

David J Posey

4

1 reference

13 January 2018

publication date

3 May 2012

1 reference

13 January 2018

published in

Psychopharmacology

1 reference

13 January 2018

volume

223

1 reference

13 January 2018

issue

2

1 reference

13 January 2018

page(s)

237-245

1 reference

13 January 2018

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Female puberty: clinical implications for the use of prolactin-modulating psychotropics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Paliperidone extended release: a review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Tolerability of paliperidone: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

A systematic review of medical treatments for children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

An open trial of risperidone in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Managing irritability and aggression in autism spectrum disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Pharmacotherapy of irritability in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Paliperidone for irritability in autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2711-3

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22549762

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22549762

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22549762

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00213-012-2711-3

1 reference

13 January 2018

1 reference

13 January 2018